Comparative Pharmacology
Head-to-head clinical analysis: FUSILEV versus PRALIDOXIME CHLORIDE AUTOINJECTOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FUSILEV versus PRALIDOXIME CHLORIDE AUTOINJECTOR.
FUSILEV vs PRALIDOXIME CHLORIDE (AUTOINJECTOR)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FUSILEV (levoleucovorin) is the pharmacologically active isomer of folinic acid. It bypasses dihydrofolate reductase inhibition by dihydrofolate reductase inhibitors (e.g., methotrexate), providing reduced folate that is used in DNA synthesis and repair. It also enhances the efficacy of fluorouracil by stabilizing the ternary complex of thymidylate synthase, thereby inhibiting DNA synthesis.
Reactivates acetylcholinesterase inhibited by organophosphate poisoning by binding to the organophosphate moiety.
Leucovorin (Fusilev) 200 mg/m2 IV over 2 hours, followed by 5-fluorouracil bolus and infusion, repeated every 2 weeks in combination regimens for advanced colorectal cancer.
1-2 g IV or IM, repeat after 1 hour if muscle fasciculations persist, then every 6-12 hours as needed. Administer as a 5% solution (1g in 20mL) over 5-10 minutes IV; IM into deltoid or anterolateral thigh.
None Documented
None Documented
The terminal elimination half-life of the active metabolite, 5-methyltetrahydrofolate (5-MTHF), is approximately 6-8 hours in healthy adults; clinically, this supports twice-daily or daily dosing schedules.
Terminal elimination half-life is approximately 1.2-2.5 hours in adults with normal renal function. In organophosphate poisoning, prolonged half-life may occur due to redistribution or renal impairment; clinical context: requires repeated dosing or continuous infusion to maintain therapeutic concentrations.
Primarily hepatic metabolism; renal excretion of metabolites accounts for approximately 40-60% of the dose; fecal excretion is negligible.
Primarily renal excretion of unchanged drug and metabolites; approximately 80-90% of a dose is excreted in urine within 4-6 hours, with 50% as unchanged pralidoxime and the remainder as metabolites (e.g., 1-methyl-2-pyridone-2-aldoxime). Minor biliary/fecal elimination (<10%).
Category C
Category C
Antidote
Antidote